umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-alpha2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Umeå University, Faculty of Medicine, Radiation Sciences, Oncology. Onkologi.
Show others and affiliations
2007 (English)In: Annals of Oncology, ISSN 0923-7534, Vol. 18, no 10, p. 1691-1697Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2007. Vol. 18, no 10, p. 1691-1697
Keywords [en]
clinical trials, dacarbazine, histamine dihydrochloride, immunotherapy, interferon alpha, interleukin-2, melanoma, phase III
Identifiers
URN: urn:nbn:se:umu:diva-16741DOI: doi:10.1093/annonc/mdm331OAI: oai:DiVA.org:umu-16741DiVA, id: diva2:156414
Available from: 2008-10-06 Created: 2008-10-06 Last updated: 2018-06-09Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records BETA

Naredi, Peter

Search in DiVA

By author/editor
Naredi, Peter
By organisation
OncologySurgery

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 39 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf